GB715813A - Improvements in derivatives of pyrimidine - Google Patents

Improvements in derivatives of pyrimidine

Info

Publication number
GB715813A
GB715813A GB12724/51A GB1272451A GB715813A GB 715813 A GB715813 A GB 715813A GB 12724/51 A GB12724/51 A GB 12724/51A GB 1272451 A GB1272451 A GB 1272451A GB 715813 A GB715813 A GB 715813A
Authority
GB
United Kingdom
Prior art keywords
methyl
chlorophenyl
phenyl
ethyl
radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB12724/51A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of GB715813A publication Critical patent/GB715813A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom

Abstract

The invention comprises compounds, having improved antimalarial properties, of the general formula <FORM:0715813/IV (b)/1> wherein Ar represents a 3- or 4-halophenyl, 3 : 4-dihalophenyl or 4-nitrophenyl radical, R represents a primary alkyl radical of 1-5 carbon atoms and X represents NH2, and their salts, and the manufacture of compounds of the said general formula wherein Ar represents any aryl radical, which may be substituted, R represents hydrogen, or an aryl or alkyl radical either of which may be substituted, and X represents hydrogen or an alkyl or aryl radical, or NH2 when R is other than hydrogen, by condensing a compound (guanidine or an amidine) of the formula X-C(: NH)NH2 with a b -alkoxy-a -arylacrylonitrile of the formula <FORM:0715813/IV (b)/2> (wherein R1 represents an alkyl or aralkyl radical). The latter reactant is preferably prepared in situ from the corresponding b -hydroxy compound (tautomeric with an a -acyl-a -arylacetonitrile). In examples: (1) a -acetyl-p-chlorophenylacetonitrile is treated with diazomethane in ether and the product is refluxed with guanidine in alcohol to produce 2 : 4-diamino - 5 - p - chlorophenyl - 6 - methylpyrimidine; the same compound is obtainable by condensing guanidine with b -ethoxy-b -methyl - a - p - chlorophenylacrylonitrile; (2) a - propionyl - p - chlorophenylacetonitrile is treated as in the first part of (1) to form 2 : 4-diamino - 5 - p - chlorophenyl - 6 - ethylpyrimidine; (3)-(5), (8)-(10) and (13) the corresponding 6 - n - propyl, 6 - isobutyl, 6-a -ethyl-n-propyl, 6-n-amyl, 6-n-undecyl, 6-b -phenethyl and 6-phenyl compounds are similarly prepared; (6) 2 : 4-diamino-5-phenyl - 6-methylpyrimidine is prepared similarly or from b - methyl - b - benzyloxy - a - phenylacrylonitrile; (7) the product of (6) is nitrated in the para-position of the 5-phenyl group; (11), (12) (14), and (24)-(35) by the process of the first part of (1) are prepared 2 : 4-diamino-5-phenyl-6 - (N - methyl - N - phenylaminomethyl)-, -5-a -naphthyl-6-methyl-, -5 : 6-diphenyl-, -5-p-chlorophenyl-6-n-butyl-, -5-p-nitrophenyl-6-ethyl-, -5-p-bromophenyl-6-ethyl-, -5-m-fluorophenyl-6-methyl-, -5-m-chlorophenyl-6-methyl-, - 5 - m - bromophenyl - 6 - methyl -, - 5 - (31 : 41-dichlorophenyl) - 6 - methyl -, - 5 - (31 : 41-dichlorophenyl) - 6 - ethyl -, - 5 - (31 : 41 - dichlorophenyl) - 6 - n - propyl -, - 5 - (31 : 41-dichlorophenyl - 6 - n - butyl -, - 5 - (31 : 41-dibromophenyl) - 6 - ethyl - and - 5 - (31-bromo - 41 - chlorophenyl) - 6 - methyl - pyrimidine; (15)-(23) from the appropriate amidines and b -methoxy-a -arylacrylonitriles are prepared 4-amino-5-phenyl-, -6-methyl-5-phenyl -, - 5 - p - chlorophenyl - 6 - phenyl -, - 2 - methyl - 5 - p - chlorophenyl -, - 5 - p-chlorophenyl - 2 : 6 - dimethyl -, - 5 - p - chlorophenyl - 2 - methyl - 6 - phenyl -, - 5 - p - chlorophenyl - 2 - p - tolyl -, - 5 - p - chlorophenyl - 6-methyl - 2 - phenyl - and - 5 - p - chlorophenyl-6-phenyl-2-p-tolyl-pyrimidine. a - Acyl - a - arylacetonitriles of the general formula <FORM:0715813/IV (b)/3> are obtainable by condensing, in the presence of an alkali metal alkoxide, arylacetonitriles with esters RCOO Alkyl, e.g. p-chlorophenylacetonitrile with ethyl propionate or ethyl benzoate, phenylacetonitrile with N-phenyl-N-methylglycine ester, or m-fluorophenylacetonitrile with ethyl acetate. Arylacetonitriles are obtainable by reacting arylmethyl halides with alkali metal cyanides, e.g. m-fluorotoluene is refluxed with sulphuryl chloride in the presence of benzoyl peroxide and the product is refluxed with potassium cyanide in aqueous ethanol to produce m-fluorophenylacetonitrile.
GB12724/51A 1950-06-14 1951-05-30 Improvements in derivatives of pyrimidine Expired GB715813A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US715813XA 1950-06-14 1950-06-14

Publications (1)

Publication Number Publication Date
GB715813A true GB715813A (en) 1954-09-22

Family

ID=22102243

Family Applications (1)

Application Number Title Priority Date Filing Date
GB12724/51A Expired GB715813A (en) 1950-06-14 1951-05-30 Improvements in derivatives of pyrimidine

Country Status (2)

Country Link
CY (1) CY135A (en)
GB (1) GB715813A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136080A (en) * 1989-12-04 1992-08-04 Burroughs Wellcome Co. Nitrile compounds
US5597828A (en) * 1988-12-07 1997-01-28 Glaxo Wellcome Inc. Certain 2,4-diamino-5-(2,3-dihalophenyl)-6-substituted pyrimidines which are pharmacologically active CNS compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597828A (en) * 1988-12-07 1997-01-28 Glaxo Wellcome Inc. Certain 2,4-diamino-5-(2,3-dihalophenyl)-6-substituted pyrimidines which are pharmacologically active CNS compounds
US5136080A (en) * 1989-12-04 1992-08-04 Burroughs Wellcome Co. Nitrile compounds

Also Published As

Publication number Publication date
CY135A (en) 1955-07-14

Similar Documents

Publication Publication Date Title
GB1377225A (en) Acylanilino compounds and herbicidal compositions containing them
GB1116693A (en) Novel cyanoalkylhydrazines
GB1161801A (en) 1,3,4-Oxadiazoles
GB715813A (en) Improvements in derivatives of pyrimidine
GB1364137A (en) 1,3,4-oxadiazolone derivatives
US4322369A (en) Preparation of alkyl cyanoacetates
GB860423A (en) Production of compounds of the pyrimidine series
US5037963A (en) Process for the preparation of symmetrical azo-dinitrile, dicarboxylic acids from keto acids
US2519957A (en) Preparation of dialkoxyalkanenitriles
GB787061A (en) Process for producing n-methyl--a-phenylsuccinimide
GB1104323A (en) 3-phenylpyrrole derivatives and process for preparing the same
US2524020A (en) Beta-chloropropionic and betachloroisobutyric acid nitriles
GB847779A (en) 2-(4-biphenylyl)-í¸-hexenoic acid esters thereof
GB1163684A (en) Process for the Preparation of Nitrilotriacetonitrile and Related Compounds.
ES266787A1 (en) New dialkyl xanthine derivatives and a process for the preparation thereof
GB768089A (en) Di-guanyl hydrazones
GB701150A (en) 3-substituted-3,4-dihydro-coumarins and process for the manufacture thereof
GB847205A (en) A process for the manufacture of ethylenimine derivatives and novel ethylenimine derivatives
GB704978A (en) Manufacture of new hydantoin compounds
GB1310685A (en) Cyclopentene derivatives
GB818724A (en) Hydantoin derivatives
GB728368A (en) Improvements in or relating to the production of 3-pyrazolidones
GB1383318A (en) Pyrimidines processes for their manufacture and uses thereof
ES341319A1 (en) Conversion of pyrazinoylcyanamides to pyrazinoylguanidines
GB807679A (en) New substituted hydantoin and thiohydantoin